Correlation between relative amounts of lipid species and number of days since the onset of symptoms among COVID-19 cases. by Spela Kokelj (8356644)

Bar chart showing the mean age at first menstruation across Indian states for the years 1992–93 and 2019–21. by MD. Nahid Hassan Nishan (22264861)

Pre and post-treatment mean EPG values on days 0, 7, 14, 21, and 28. by Sohail Afzal (10850709)

Increased or reduced ATGL-1 activity does not significantly change <i>N. parisii</i> growth. by Hala Tamim El Jarkass (16625309)

Forest plots illustrate the mean difference in; (A) hospital stay, (B) ICU stay, (C) intubation time; with subgroup analysis. by Mohamed R. Abdelraouf (21501468)

related to Fig 3. (A) Live eggs induce AIM2 pyroptosome formation. Microscopy of AIM2-citrine macrophages stimulated with live eggs for 48 h. by Madhusoodhanan Suresh Kumar Meena Kumari (20896666)

Eggs jointly coordinate a caspase-1 and caspase-8 dependent pyroptotic cell death. by Madhusoodhanan Suresh Kumar Meena Kumari (20896666)

related to Fig 4. ROS, K+ efflux and cathepsin B do not affect TNFα production in response to eggs. by Madhusoodhanan Suresh Kumar Meena Kumari (20896666)

ROS, K⁺ efflux and cathepsin B are required for NLRP3 activation. by Madhusoodhanan Suresh Kumar Meena Kumari (20896666)

Paired influent and effluent concentrations of total coliforms (panel A), heterotrophic plate count (panel B), and male-specific coliphages (panel C) across POU UVC LED devices ins... by Hania Zanib (21864477)

Mean signal intensities obtained for each analyte at three different tissue-to-solvent volume proportions. by Ewa Paszkowska (21246702)

Mean persistence (±SE) of GO and GO-GA NPs on <i>Callosobruchus maculatus.</i> by Huda H. Elbehery (22492996)

Preoperative background characteristics of the patients. by Yasuyuki Sotani (20114144)

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Time course of central retinal thickness (CRT) in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean CRT (μm ± standard deviation) significantly decreased from 504.7 ± 118.2 μm preoperatively to 302.5 ± 60.5 at 1 month, 307.5 ± 64.4 at 3 months, 286.8 ± 49.0 at 6 months, 305.3 ± 79.5 at 12 months, 288.8 ± 79.1 at 24 months, and 295.2 ± 87.4 at 36 months (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…These values significantly decreased in the first postoperative year to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0, and 3.1 ± 2.8; in the second year to 2.1 ± 2.8, 0.4 ± 1.0, 0.0, 0.1 ± 0.3, and 2.6 ± 2.8; and in the third year to 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 (Kruskal–Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g007" target="_blank">Fig 7</a>). …”

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…These significantly decreased to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0.0, and 3.1 ± 2.8 in the first year; 2.1 ± 2.8, 0.4 ± 1.0, 0, 0.1 ± 0.3, and 2.6 ± 2.8 in the second year; and 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 in the third year (Kruskal–Wallis test, p < 0.001; Dunn’s test, *P < 0.05, **P < 0.01). …”

Time course of optical coherence tomography and fundus findings in a representative non-recurrent eye. by Yasuyuki Sotani (20114144)

Time course of best-corrected visual acuity (BCVA) in all eyes. by Yasuyuki Sotani (20114144)

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)